Melanoma: all 3,073 studies

Page 17 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)CompletedNCT04547946
• A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
• Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical ResectionNo longer availableNCT04544202
• Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1
• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
• A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLCStatus unknownNCT04521075Phase 1/2
• Passive Versus Active Educational Interventions for Melanoma RecognitionCompletedNCT04507048Not applicable
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2
• Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/MelanomaCompletedNCT04490564
• Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaNo longer availableNCT04489433
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 1
• Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and MelanomaActive, not recruitingNCT04478318Not applicable
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsActive, not recruitingNCT04478279Phase 1/2
• BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 DrugsTerminatedNCT04473027
• Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaStatus unknownNCT04472806Phase 2
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaActive, not recruitingNCT04464759Phase 1/2
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1
• Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.CompletedNCT04460053Not applicable
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1TerminatedNCT04455503Phase 1/2
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1
• PD-L1 Expression in Cancer (PECan Study).Status unknownNCT04436406Not applicable
• Neoadjuvant T-VEC in High Risk Early MelanomaSuspendedNCT04427306Phase 2
• A Study of DF6002 Alone and in Combination With NivolumabCompletedNCT04423029Phase 1
• JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 1
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2
• Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaCompletedNCT04417530Phase 2
• Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingNCT04407247Phase 1/2
• Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaStatus unknownNCT04397770Phase 2
• OH2 Injection in Solid TumorsCompletedNCT04386967Phase 1/2
• Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk PatientsActive, not recruitingNCT04385732Not applicable
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
• Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)CompletedNCT04364230Phase 1/2
• The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of MelanomaStatus unknownNCT04357509Phase 1
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaActive, not recruitingNCT04356729Phase 2
• Atypical MOLes and Melanoma Early Detection Study (MoleMed)Status unknownNCT04353050Not applicable
• IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal MelanomaCompletedNCT04335890Phase 1
• Hydrochlorothiazide and Risk of Skin CancerCompletedNCT04334824
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedNCT04330430Phase 2
• A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingNCT04328844Phase 1
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaActive, not recruitingNCT04309409Phase 3
• Infliximab for Treatment of Immune Checkpoint Inhibitor ColitisActive, not recruitingNCT04305145Phase 2
• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
• Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and AngiosarcomaCompletedNCT04293289Not applicable
• Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsActive, not recruitingNCT04291105Phase 2
• Prevention of Recurrence and Metastasis in Genetically High-Risk MelanomasWithdrawnNCT04285749Early Phase 1
• The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryTerminatedNCT04277663Phase 3
• Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II MelanomaCompletedNCT04274816Phase 1
• A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
• Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast CancerStatus unknownNCT04261179Phase 4
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• Comparison of PET/CT and Ultrasound in Staging of Malignant MelanomaCompletedNCT04253574
• Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint InhibitorsCompletedNCT04253080Not applicable
• A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2
• Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type MelanomaStatus unknownNCT04248387Phase 2
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1
• Surgery of Melanoma Metastases After Systemic TherapyWithdrawnNCT04242329Phase 2
• Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .Status unknownNCT04234620
• Fast Track Diagnosis of Skin Cancer by Advanced ImagingCompletedNCT04229277Not applicable
• Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
• TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced MelanomaCompletedNCT04217473Phase 1
• Pre Transplantation MelanomaCompletedNCT04217382
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
• Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From MelanomaStatus unknownNCT04206358Phase 1
• A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma PatientsStatus unknownNCT04200040Phase 2
• Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced MelanomaActive, not recruitingNCT04197882Phase 1
• A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)Active, not recruitingNCT04196452
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedNCT04190628Phase 1
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• Toripalimab in Combination With Axitinib in Patients With Localized Mucosal MelanomaStatus unknownNCT04180995Phase 2
• Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney CancerCompletedNCT04180774Phase 1/2
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsCompletedNCT04172454Phase 1/2
• Polish Microbiome MapStatus unknownNCT04169867
• Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CTTerminatedNCT04168528Phase 1/2
• Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for MelanomaCompletedNCT04165967Phase 1
• Clinical Utility of Electrical Impedance SpectroscopyStatus unknownNCT04161742Not applicable
• Immune Monitoring in Metastatic MelanomaStatus unknownNCT04158544
• Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsCompletedNCT04157985Phase 3
• Appropriate Dosing to Optimise Personalised Cancer TreatmentsCompletedNCT04154163
• An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in AustraliaCompletedNCT04146324
• Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruitingNCT04140500Phase 1/2
• BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsStatus unknownNCT04136470
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2
• NovoTTF-200A + Pembrolizumab In Melanoma Brain MetastasisWithdrawnNCT04129515Phase 1/2
• PVSRIPO in Combination With Nivolumab in MelanomaWithdrawnNCT04125719Phase 1
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
• IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaCompletedNCT04109456Phase 1
• A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin CancerWithdrawnNCT04099446
• GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingNCT04083599Phase 1/2
• SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)Active, not recruitingNCT04079166Phase 2
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabActive, not recruitingNCT04074967Phase 1/2
• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingNCT04074096Phase 2
• A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownNCT04072900Phase 1
• Whack-a-Mole: Testing an Intervention to Increase Melanoma IdentificationCompletedNCT04069104

← Melanoma overview